Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL
Status:
Terminated
Trial end date:
2019-02-13
Target enrollment:
Participant gender:
Summary
To characterize safety, tolerability and to establish the maximum tolerated dose (MTD) for
Tenalisib in combination with Pembrolizumab in patients with cHL.